Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 19;11(2):624.
doi: 10.3390/biomedicines11020624.

Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset

Affiliations

Ocular Behçet Disease-Clinical Manifestations, Treatments and Outcomes According to Age at Disease Onset

Michael Ostrovsky et al. Biomedicines. .

Abstract

Behçet disease (BD) is a multisystemic disease that commonly involves the eyes. Although it affects patients in all age groups, data on ocular disease by age of onset are limited. This retrospective, multicenter study aimed to compare epidemiology, systemic and ocular manifestations, treatments and outcomes between three age groups: juvenile (<18 years), adult (18-39 years) and late (≥40 years) disease onset. The study included 175 ocular BD patients (303 eyes) from Israel and Palestine: juvenile-onset (n = 25, 14.3%), adult-onset (n = 120, 68.6%) and late-onset (n = 30, 17.1%). Most patients in all groups were male. Systemic manifestations were similar in all groups. Systemic co-morbidities were more common in late-onset patients. Bilateral panuveitis was the most common ocular manifestation in all patients. Non-occlusive retinal vasculitis, peripheral vessel occlusions, cataract and elevated intraocular pressure were found more commonly among juvenile-onset eyes. Anterior uveitis and macular ischemia were most common among late-onset eyes, while branch retinal vein occlusion was most common in adult and late-onset eyes. All patients were treated with corticosteroids. Methotrexate, immunomodulatory combinations and biologic treatments were more commonly used for juvenile-onset patients. All groups had a similar visual outcome. Our study showed that patients with ocular BD have varied ocular manifestations and require different treatments according to age of disease onset, but visual outcome is similar.

Keywords: Behçet disease; Behçet uveitis; adult-onset Behçet disease; juvenile-onset Behçet disease; late-onset Behçet disease; ocular Behçet disease; uveitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mean best-corrected visual acuity from baseline to 60 months. ANOVA test was performed to compare the best-corrected visual acuity between all groups at each time point. There was no statistically significant difference between the groups at all time points.

References

    1. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet’s Disease. N. Engl. J. Med. 1999;341:1284–1291. doi: 10.1056/NEJM199910213411707. - DOI - PubMed
    1. Alpsoy E., Leccese P., Emmi G., Ohno S. Treatment of Behçet’s Disease: An Algorithmic Multidisciplinary Approach. Front. Med. 2021;8:624795. doi: 10.3389/fmed.2021.624795. - DOI - PMC - PubMed
    1. Bettiol A., Prisco D., Emmi G. Behçet: The syndrome. Rheumatology. 2020;59((Suppl. S3)):iii101–iii107. doi: 10.1093/rheumatology/kez626. - DOI - PubMed
    1. Pain C.E. Juvenile-onset Behçet’s syndrome and mimics. Clin. Immunol. 2020;214:108381. doi: 10.1016/j.clim.2020.108381. - DOI - PubMed
    1. Koné-Paut I. Behçet’s disease in children, an overview. Pediatr. Rheumatol. 2016;14:10. doi: 10.1186/s12969-016-0070-z. - DOI - PMC - PubMed

LinkOut - more resources